Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-09-2014 | Case Report

Remission of Microangiopathy in Transplanted Thalassemic Child

Authors: Priya Marwah, Rajpreet Soni, Lawrence Faulkner, Mohammed El Missiry, Cornelio Uderzo

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Abstract

Transplant associated thrombotic microangiopathy is a severe complication of Hematopoeitic stem cell transplantation. Although there is agreement in terms of diagnostic criteria, treatment options are not clarified yet. We present a patient aged 2.6 years who developed transplant associated thrombotic microangiopathy after allogeneic bone marrow transplantation and to discuss both risk factors and possible spontaneous remission of transplant associated thrombotic microangiopathy.

Ho VT, Cutler C, Carter S et al (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoetic stem cell transplantation. Biol Blood Marrow Transpl 11:571–575CrossRef

Uderzo C, Bonanomi S et al (2006) Risk factors and severe outcome in Thrombotic Microangiopathy after allogeneic hematopoetic stem cell transplantation. Transplantation 82:638PubMedCrossRef

Cutler C, Henry NL, Magee C et al (2005) Sirolimus and thrombotic microangiopathy after allogeneic hematopoetic stem cell transplantation. Biol Blood Marrow Transpl 11:551–557CrossRef

Stavrou E, Lazarus HM (2010) Thrombotic microangiopathy in hematopoetic cell transplantation: an update. Mediterr J Hemat Infect Dis 2(3):e 2010033. doi:10.4084/MJHID.2010.033 CrossRef

Shimoni et al (2004) Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced intensity conditioning. The incidence is not reduced. Biol Blood Marrow Transpl 10:484CrossRef

Busca A, Uderzo C (2000) Bone marrow transplant associated thrombotic microangiopathy. Hematology 5:53PubMed

Grigg a et al (1995) Disseminated fungal infection and early onset microangiopathy after allogeneic bone marrow transplantation. Bone Marrow Transpl 15:795

Uderzo C, Fumagilli M et al (2000) Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing BMT. Bone Marrow Transpl 26:1005CrossRef

Cho BS, Yahng SA, Lee SE et al (2010) Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoetic stem cell transplantation. Transplantation 90(8):918–926PubMedCrossRef

10.

Moore JC, Arnold DM, Leber BF et al (2007) Intravenous immunoglobulins as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sang 93:173–175PubMedCrossRef

11.

Wolff d, Wilhelm s, Hahn J et al (2006) Replacement of calcineurin inhibitors with daclizumab in patients with transplant associated microangiopathy or renal insufficiency associated with GVHD. Bone Marrow Transpl 38:445–451CrossRef

12.

Wy Au, Ma ES, Lee TL et al (2007) Successful treatment of thrombotic microangiopathy after hematopoetic stem cell transplantation with rituximab. Br J Hematol 137:475–478CrossRef

13.

Ho VT, Linden E, Revia c et al (2007) Hepatic veno occlusive disease after hematopoetic stem cell transplantation: review and update on the use of Defibrotide. Semin Thromb Hemost 33:373–388PubMedCrossRef

14.

Bullery SR, Strahm B, Doyle J et al (2007) Defibrotide for the treatment of VOD in children. Pediatr Blood and cancer 48:700–704CrossRef

15.

Corti p, Uderzo c et al (2002) Defibrotide as promising treatment of thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transpl 29:542CrossRef

16.

Ulutin ON (1993) Anti thrombotic effect and clinical potential of DFT. Semin Thromb Hemost 19:186PubMed

17.

Laski bl, Goebel J, Davis S, Jodele S (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation- associated thrombotic microangiopathy. Blood 118(6):1452–1462CrossRef

Title: Remission of Microangiopathy in Transplanted Thalassemic Child
Authors: Priya Marwah
Rajpreet Soni
Lawrence Faulkner
Mohammed El Missiry
Cornelio Uderzo
Publication date: 01-09-2014
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-014-0404-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2014

Hepatosplenic T Cell Lymphoma

Hb Knossos: HBB:c.82G>T Associated with HBB:c.315+1G>A Beta Zero Mutation Causes Thalassemia Intermedia

Pyrexia, Lung nodules, Granulomas: Pulmonary Lymphomatoid Granulomatosis

A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy

Pure Red Cell Aplasia: A Rare Complication of Isoniazid Therapy

A Colonization of a Different Kind

Keynote webinar | Spotlight on antibody–drug conjugates in cancer